RNA · 2023 · 18 citations · 50 references
MedicineMolecular BiologyOncologyBiomedical ImagingHistopathologyMolecular ImagingBiomarkers Of Liver InjuryHepatic Drug DistributionHepatobiliary ImagingImmunohistochemistryLiver ImagingQuantitative Molecular ImagingCoherent Anti-stokes Raman MicroscopyCoherent Anti-stokes Raman Scattering MicroscopyCoherent Anti-stokes Raman SpectroscopyImmunohistochemical DetectionIn Vivo Tissue CharacterizationLineage-specific MarkersQuantitative In Situ HybridizationSubcellular Imaging
Current methods for detecting unlabeled antisense oligonucleotide (ASO) drugs rely on immunohistochemistry (IHC) and/or conjugated molecules, which lack sufficient sensitivity, specificity, and resolution to fully investigate their biodistribution. Our aim was to demonstrate the qualitative and quantitative distribution of unlabeled bepirovirsen, a clinical stage ASO, in livers and kidneys of dosed mice using novel staining and imaging technologies at subcellular resolution. ASOs were detected in formalin-fixed paraffin-embedded (FFPE) and frozen tissues using an automated chromogenic in situ hybridization (ISH) assay: miRNAscope. This was then combined with immunohistochemical detection of cell lineage markers. ASO distribution in hepatocytes versus nonparenchymal cell lineages was quantified using HALO AI image analysis. To complement this, hyperspectral coherent anti-Stokes Raman scattering (HS-CARS) imaging microscopy was used to specifically detect the unique cellular Raman spectral signatures following ASO treatment. Bepirovirsen was localized primarily in nonparenchymal liver cells and proximal renal tubules. Codetection of ASO with distinct cell lineage markers of liver and kidney populations aided target cell identity facilitating quantification. Positive liver signal was quantified using HALO AI, with 12.9% of the ASO localized to the hepatocytes and 87.1% in nonparenchymal cells. HS-CARS imaging specifically detected ASO fingerprints based on the unique vibrational signatures following unlabeled ASO treatment in a totally nonperturbative manner at subcellular resolution. Together, these novel detection and imaging modalities represent a significant increase in our ability to detect unlabeled ASOs in tissues, demonstrating improved levels of specificity and resolution. These methods help us understand their underlying mechanisms of action and ultimately improve the therapeutic potential of these important drugs for treating globally significant human diseases.
50
Fay Wang, John J. Flanagan, Nan Su et al. · Journal of Molecular Diagnostics · 2011 · 2.7K citations · Full text
Using Raman spectroscopy to characterize biological materials
Holly J. Butler, Lorna Ashton, Benjamin Bird et al. · Nature Protocols · 2016 · 1.2K citations · Full text
Natural Sciences, Bioengineering, Biomedical Engineering +14